AbbVie’s Skyrizi (risankizumab) Receives Health Canada’s Approval for Moderate to Severe Plaque Psoriasis

 AbbVie’s Skyrizi (risankizumab) Receives Health Canada’s Approval for Moderate to Severe Plaque Psoriasis

AbbVie’s Skyrizi (risankizumab) Receives Health Canada’s Approval for Moderate to Severe Plaque Psoriasis

Shots:

  • The Health Canada approval is based on four P-III studies ultIMMa-1, ultIMMa-2, IMMvent and IMMhance assessing Skyrizi (risankizumab) vs PBO, adalimumab, ustekinumab in >2000 adult patients with moderate to severe plaque psoriasis
  • The collective studies result: @16wks. sPGA 0/1 & PASI 90 (88%, 84% & 75%); Skyrizi vs adalimumab, PASI 90 (72% vs 47%); Skyrizi vs ustekinumab, DLQI score (66% & 67% vs 43% & 47%); Skyrizi vs PBO, @28wks. sPGA 0/1 (87.4% vs 61.3%); improvement in  skin clearance with 3mos.dose regimen
  • Skyrizi (risankizumab) is a humanized immunoglobulin mAb inhibits IL-23 by binding to its p19 subunit. On Mar’16, Boehringer Ingelheim & AbbVie collaborated to develop & commercialize Skyrizi globally

Click here to read full press release/ article | Ref: PRnewswire | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post